Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00783367 · OUTCOME

Time Until Progression After Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphomas With Rituximab Resistance

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas · Source last updated 2023-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
9 years from enrollment of first subject

What was measured

Progression free survival time in months

Analysis population: Subjects who received both Revlimid and rituximab were evaluable for response

Groups in this outcome

Cohort 1

Revlimid + rituximab with dexamethasone

Cohort 2

Revlimid + rituximab (without dexamethasone)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 126
Cohort 219

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 122.2Not reported11.460.8Not reported
Cohort 222.4Not reported7.730.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        11.4
        upper Limit
        60.8
        value
        22.2
      2. group Id
        OG001
        lower Limit
        7.7
        upper Limit
        30.1
        value
        22.4
denoms
  1. counts
    1. group Id
      OG000
      value
      26
    2. group Id
      OG001
      value
      19
    units
    Participants
description
Progression free survival time in months
dispersion Type
95% Confidence Interval
groups
  1. description
    Revlimid + rituximab with dexamethasone
    id
    OG000
    title
    Cohort 1
  2. description
    Revlimid + rituximab (without dexamethasone)
    id
    OG001
    title
    Cohort 2
param Type
MEDIAN
population Description
Subjects who received both Revlimid and rituximab were evaluable for response
reporting Status
POSTED
time Frame
9 years from enrollment of first subject
title
Time Until Progression After Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphomas With Rituximab Resistance
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice